{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'important to clinically evaluate the event, as applicable. This information, in conjunction with the', 'e-diary record, will be used by the Investigator to verify or reject the event recorded in the diary as an', 'HAE attack. All Investigator-confirmed attacks of HAE must include symptoms of swelling;', 'prodromal symptoms in the absence of swelling are not considered HAE attacks, regardless of', 'treatment. Symptoms of swelling, in addition to visible swelling, may also include symptoms in the', 'oropharyngeal or abdominal regions which are indicative of internal swelling.', 'The main study will be comprised of adult subjects (> 18 years of age); a substudy in participating', 'regions will be included that allows adolescent subjects > 12 to 17 years of age to screen and enroll.', 'Main study and substudy subjects will be randomized via a separate randomization scheme; however,', 'study-mandated procedures will be identical, and analyses will include all subjects who participate in', 'the study.', 'Safety and tolerability will be evaluated through assessments of AEs, laboratory analyses (clinical', 'chemistry, hematology, and urinalysis), vital signs, electrocardiograms (ECGs), and physical', 'examinations.', 'Study visits in Part 1 will occur at screening, baseline, and Weeks 2, 4, 8, 12, 18, and 24. The primary', 'efficacy analysis will occur after the last subject completes their Week 24 visit and will include all', 'data through Week 24. Subject treatment will remain blinded to the subject, site, and Sponsor staff', 'interacting with sites during Part 2.', 'Part 2 (24-week evaluation of safety of blinded BCX7353)', 'Part 2 of the study will start with the administration of the study drug dispensed at the Week 24 visit.', 'Subjects in Groups 1 and 2 will continue to receive the same BCX7353 dose to which they were', 'randomized in Part 1 of the study in a blinded manner. Subjects randomized to Group 3 (placebo) will', 'undergo a second randomization in a 1:1 ratio to receive either a 110 or 150 mg dose in a blinded', 'manner beginning at the Week 24 visit (see figure below for visual depiction of treatments in all study', 'parts). The active dose a subject receives in Part 2 will be blinded for all subjects; subjects will be', 'informed that they will receive an active dose of BCX7353 in Part 2.', 'Study visits during Part 2 will occur during Weeks 26, 28, 32, 36 and 48, with telephone contact at', 'Weeks 40 and 44. Subjects will continue to document all angioedema attacks that occur while on', 'study drug in their e-diary and will have regular visits to assess safety and tolerability; Investigator', 'confirmation of attacks will continue to be required for Part 2. Interim safety analyses will be', 'conducted while Part 2 is ongoing to support regulatory filings.', 'Part 3 (up to 96-week evaluation of safety of open-label BCX7353)', 'Part 3 of the study will start with the administration of the study drug dispensed at the Week 48 visit.', \"Based on the results of the current study's Part 1 analysis of greater efficacy and no increase in safety\", 'or tolerability risk at the 150 mg dose vs. the 110 mg dose, all subjects will be transitioned to the', '150 mg dose of BCX7353 on or after their Week 48 visit, regardless of their initial or Week 24', 'treatment allocation.', 'Study visits during Part 3 will occur during Weeks 60, 72, 84, 96 and approximately every 12 weeks', 'thereafter, for a study duration of up to 144 weeks (approximately 3 years), or until another', 'mechanism is available to provide drug to the subject (eg, market access) or the Sponsor discontinues', 'development of the product for the prevention of angioedema attacks, whichever comes first.', 'Telephone contact will occur at Weeks 52, 56, 64, 68, 76, 80, 88, and 92. A final study follow-up visit', 'will be scheduled approximately 3 weeks following the last administration of study drug. Investigator', 'confirmation of attacks will not be required in Part 3. All attacks recorded by the subjects will be', 'reviewed and confirmed or rejected according to a set of pre-defined rules prior to inclusion in the', 'effectiveness analyses. These rules, which will be constructed in concert with HAE-treating', 'physicians, will be outlined in the Statistical Analysis Plan.', '9']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'Prospective Angioedema Event Run-In', 'Part 1 dosing: Day 1 to Week 24', 'Part 2 dosing:', 'Part 3 dosing:', 'Period to Establish Eligibility', '(Day 168)', 'Weeks 24 to 48', 'Weeks 48 to up to 144', '14 to 56 days from screening visit', '110 mg BCX7353 QD', '110 mg BCX7353 QD', '110 mg BCX7353 QD', 'until transitioned to', 'x 24 weeks (Group 1)', '24 weeks (Group 1)', '150 mg (Group 1)', 'Screening', 'visit', '1:1:1 ratio', '150 mg BCX7353 QD', '150 mg BCX7353 QD', '150 mg BCX7353 QD x', 'x 24 weeks (Group 2)', 'x 24 weeks (Group 2)', '96 weeks (Group 2)', '110 mg BCX7353 QD', '110 mg BCX7353 QD', 'until transitioned to', '24 weeks (Group 3a)', '150 mg (Group 3a)', 'Placebo QD', '2nd randomization at', 'x 24 weeks (Group 3)', 'Week 24: 1:1 ratio', '150 mg BCX7353 QD', '150 mg BCX7353 QD x', '24 weeks (Group 3b)', '96 weeks (Group 3b)', 'Screening Period', 'Treatment Period', '< 10 weeks from Screening visit to Day 1', 'Day 1 up to Week 144', 'Diary recording and investigator confirmation of attacks', 'Number of subjects (planned):', 'Approximately 96 subjects will be enrolled in this study (n = 32/group), which includes any', 'adolescent subjects enrolled in the substudy.', 'A blinded interim analysis is planned to estimate the standard deviation from the pooled treatment', 'groups after 50% of the subjects complete Part 1 of the study (through 24 weeks). The sample size', 'may be re-estimated based on the variability from the pooled data.', 'The final sample size will be the maximum of either the original planned sample size (32 per group)', 'or the re-estimated sample size. No statistical adjustment for the final analysis is planned.', 'Main criteria for inclusion:', '1. Males and non-pregnant, non-lactating females > 18 years of age (main study) or > 12 to', '17 years of age (substudy).', '2.', 'Able to provide written, informed consent. Subjects aged 12 to 17 years who are screening', 'for the substudy must be able to read, understand, and be willing to sign an assent form in', 'addition to a caregiver providing informed consent.', '3. Subject weight of > 40 kg.', '4. A clinical diagnosis of hereditary angioedema Type I or II, defined as having a C1-esterase', 'inhibitor (C1-INH) functional level below 50% and a complement 4 (C4) level below the', 'lower limit of the normal (LLN) reference range, as assessed during the Screening period.', 'In the absence of a low C4 value drawn during the intercritical period (ie, subject is not', 'having an HAE attack), 1 of the following is acceptable to confirm the diagnosis of HAE:', '1) a SERPING-1 gene mutation known or likely to be associated with HAE Type I or II', 'assessed during the screening period; 2) a confirmed family history of C1-INH', 'deficiency; 3) a C4 redrawn and retested during an attack in the screening period with the', 'results below the LLN reference range.', '10']\n\n###\n\n", "completion": "END"}